Entries |
Document | Title | Date |
20080206270 | Enhancing Class I Antigen Presentation With Synthetic Sequences - The invention relates generally to the treatment and prevention of human cancer and viral diseases. More specifically, this invention relates to development of a new generation of vaccines that rely on eliciting cellular immune responses, specifically induction of cytotoxic T lymphocytes (CTL), against cancer cells and virus-infected cells via administration of a vaccine comprising a fusion peptide or a modified peptide. Such a fusion peptide is composed of an insertion signal sequence and a peptide derived from a tumor antigen or a viral antigen, which improves antigen presentation and induces CTL with higher efficiency against cancer cells and virus-infected cells. An exemplary antigen utilized in the invention is HER2/neu. The peptides peptide vaccines of the invention are derived from the antigens PRAME, OFA/iLRP, STEAP and SURVIVIN. | 08-28-2008 |
20080206271 | FUSION ANTIGEN USED AS VACCINE - Fusion antigen used as vaccine. The invention relates to a fusion antigen specific for a target cell. The fusion antigen contains a ligand moiety, a | 08-28-2008 |
20080213295 | HER-2/NEU FUSION PROTEINS - The present invention is generally directed to HER-2/neu fusion proteins, nucleic acid molecules encoding HER-2/neu fusion proteins, viral vectors expressing HER-2/neu fusion proteins, and pharmaceutical compositions (e.g., vaccines) comprising the HER-2/neu fusion proteins and/or nucleic acid molecules encoding the HER-2/neu fusion proteins. The present invention is also directed to methods of treating or preventing cancer by eliciting or enhancing an immune response to the HER-2/neu protein, including for uses in the treatment of malignancies associated with the HER-2/neu oncogene. | 09-04-2008 |
20080220011 | Use of Flagellin in Tumor Immunotherapy - The invention provides a fusion protein comprising a flagellin adjuvant and a tumor antigen. Also provided are compositions comprising a flagellin adjuvant and a tumor antigen. The invention further provides pharmaceutical formulations and methods for inducing an immune response against a tumor antigen and methods of treating a tumor in a subject. | 09-11-2008 |
20080226667 | Innate immune system-directed vaccines - The present invention provides novel vaccines, methods for the production of such vaccines and methods of using such vaccines. The novel vaccines of the present invention combine both of the signals necessary to activate native T-cells—a specific antigen and the co-stimulatory signal—leading to a robust and specific T-cell immune response. | 09-18-2008 |
20080233142 | Use of penetration enhancers and barrier disruption methods to enhance the immune response of an antigen - A transcutaneous immunization system where the topical application of an adjuvant and an antigen or nucleic acid encoding for an antigen, to intact skin induces a systemic or mucosol antibody response. The immune response so elicited can be enhanced by physical or chemical skin penetration enhancement. | 09-25-2008 |
20080248057 | Multivalent immunogenic composition containing RSV subunit compostion and influenza virus preparation - Immunogenic compositions for administration to adults particularly to the elderly, to protect them against disease caused by infection by respiratory syncytial virus and influenza virus comprise an immunoeffective amount of a mixture of purified fusion (F) protein, attachment (G) protein and matrix (M) protein of RSV and an immunoeffective amount of a non-virulent influenza virus preparation. The components of the composition when formulated as a vaccine for in vivo administration do not impair the immunogenicity of each other. The immunogenic composition may also contain an adjuvant. | 10-09-2008 |
20080254052 | MOLECULAR DIFFERENCES BETWEEN SPECIES OF THE M. TUBERCULOSIS COMPLEX - Specific genetic deletion are identified in mycobacteria isolates, including variations in the | 10-16-2008 |
20080260769 | Polypeptides for Oligomeric Assembly of Antigens - A system for expressing antigenic polypeptides in oligomeric form fuses the antigenic polypeptide to an oligomerisation polypeptide such that the oligomerisation polypeptide can interact with other oligomerisation polypeptides and bring multiple copies of the antigenic polypeptide into close proximity in the form of an oligomer. Expressing the polypeptides in oligomeric form in this way can improve their immunogenicity compared to a monomeric form. | 10-23-2008 |
20080317773 | Conjugates that contain the homeodomain of antennapedia - The subject invention pertains to a conjugate comprising: (a) a first region comprising the homeodomain of antennapedia or a variant thereof, and (b) a second region not naturally associated with the first region. In one embodiment, the second region of the conjugate comprises a protein of at least 100 amino acids. | 12-25-2008 |
20090017056 | SKIN IMMUNIZATION USING LT-STA FUSION PROTEINS - This invention includes fusion proteins comprising a bacterial ADP-ribosylating exotoxin (bARE), or a variant or portion thereof, fused to a STa exotoxin, or a portion or variant thereof. Optionally, the exotoxins are fused via a peptide linker. The invention also includes compositions formulated for transcutaneous immunizations and/or induction of an immune response by epicutaneous administration comprising an effective amount of a fusion protein comprising a bacterial ADP-ribosylating exotoxin fused to a STa exotoxin. Optionally, the exotoxins are fused via a peptide linker. | 01-15-2009 |
20090028893 | Methods for producing fusion polypeptides or enhancing expression of fusion polypeptides - The present invention relates to the cloning and expression of foreign protein or polypeptides in bacteria, such as | 01-29-2009 |
20090028894 | Papilloma Virus Capsomere Vaccine Formulations and Methods of Use - Vaccine formulations comprising viral capsomeres are disclosed along with methods for their production. Therapeutic and prophylactic methods of use for the vaccine formulations are also disclosed. | 01-29-2009 |
20090041798 | LEISHMANIA STEROL 24-C-METHYLTRANSFERASE COMPOSITIONS FOR THE PREVENTION, TREATMENT AND DIAGNOSIS OF LEISHMANIASIS - Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise | 02-12-2009 |
20090081248 | Non-hemolytic LLO fusion proteins and methods of utilizing same - The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin O (LLO) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The present invention also provides methods of utilizing recombinant proteins, peptides, nucleotide molecules, and vaccine vectors of the present invention to induce an immune response to a peptide of interest. | 03-26-2009 |
20090098154 | Yeast-Based Vaccines As Immunotherapy - Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed. | 04-16-2009 |
20090117144 | Recombinant flu vaccines - The present invention provides compositions for use as vaccines against the influenza virus, and rapid methods of producing such compositions. The composition include i) at least one peptide derived from an influenza virus, wherein the peptide is fused to a capsid protein derived from a plant virus forming a recombinant capsid fusion peptide and ii) at least one isolated antigenic protein or protein fragment derived from a human or avian influenza virus. The isolated antigenic protein or protein fragment derived from the human or avian influenza virus can be conjugated to the surface of the recombinant capsid fusion peptide. | 05-07-2009 |
20090117145 | Composition and Method For Enhancing Immune Response - A composition and method for enhancing immune response in a living organism is disclosed. In particular, the present disclosure provides an adjuvant peptide for use in raising an immune response to an antigen. The adjuvant peptide is selected from a group of peptides with an HIV-related sequence. Additionally, the adjuvant peptide can comprise a fusion-protein that acts as a mucosal adjuvant. The adjuvant peptide can be transformed into one or more living cells, such that the mucosal adjuvant can be produced in living cells and then administered by systemic, mucosal or epidermal delivery. | 05-07-2009 |
20090130136 | Chondroitin Sulphate a Binding Domains - The invention is related to the identification of CSA binding domains in var2CSA homologs from different parasite strains and furthermore to an isolated polypeptide comprising a CSA-binding domain sequence substantially as shown in SEQ ID NO:1, or functional equivalent thereof, or the corresponding portion of PfEMP1 from a strain of | 05-21-2009 |
20090136536 | Recombinant Subunit Vaccine - A method is provided of producing an immunogenic complex comprising a heat shock protein (hsp) coupled to a heterologous antigenic polypeptide, which method comprises: (a) expressing the antigenic polypeptide in a cell which cell has been subjected to a stimulus which causes the induction of a heat shock response in said cells; and (b) recovering the antigenic polypeptide coupled to one or more hsps from said cell or the culture medium. Also provided are immunogenic compositions comprising a heat shock protein (hsp) derived from a non-mammalian eukaryote coupled to a heterologous antigenic polypeptide which composition is capable of inducing an immune response to said antigenic polypeptide in a human or animal. | 05-28-2009 |
20090136537 | Lipopeptide compositions and methods of use therof - Compositions comprise lipopeptides, antigens and emulsifying agents. The compositions are used to stimulate an immune response in a subject. | 05-28-2009 |
20090142367 | Yeast-Based Vaccines As Immunotherapy - Compositions and methods for treating and/or preventing a variety of diseases and conditions that are amenable to immunotherapy and, in one particular embodiment, compositions and methods for treating and/or preventing cancer in an animal are described. Specifically improvements related to the use of a yeast-based vaccine comprising a yeast vehicle and an antigen that is selected to elicit an antigen-specific cellular and humoral immune response in an animal, for use in prophylactic and/or therapeutic vaccination and the prevention and/or treatment of a variety of diseases and conditions are disclosed. | 06-04-2009 |
20090142368 | Chemically Programmable Immunity - The present invention is related to methods and compositions that are capable of immediately immunizing a human or animal against any molecule or compound. The present invention comprises an immunity linker molecule with at least two sites; (1) a first binding site that binds to an immune system molecule in a human or animal that has been preimmunized against the first binding site, and (2) one or more second binding sites that bind specifically to a desired compound or molecule. The first binding site and the second binding site(s) are linked by a linker portion of the molecule. | 06-04-2009 |
20090148471 | Molecular Vaccine Linking an Endoplasmic Reticulum Chaperone Polypeptide to an Antigen - This invention provides compositions and methods for inducing and enhancing immune responses, such as antigen-specific cytotoxic T lymphocyte (CTL) responses, using chimeric molecules comprising endoplasmic reticulum chaperone polypeptides and antigenic peptides. In particular, the invention provides compositions and methods for enhancing immune responses induced by polypeptides made in vivo by administered nucleic acid, such as naked DNA or expression vectors, encoding the chimeric molecules. The invention provides a method of inhibiting the growth of a tumor in an individual. The invention also provides novel self-replicating RNA virus constructs for enhancing immune responses induced by chimeric polypeptides made in vivo. | 06-11-2009 |
20090148472 | IDENTIFICATION OF PROTECTIVE ANTIGENIC DETERMINANTS OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS AND USES THEREOF - The invention relates to a polypeptide of a protective antigenic determinant (PAD polypeptide) of porcine reproductive and respiratory syndrome virus (PRRSV) and nucleic acids encoding a PAD polypeptide. The PAD polypeptide and nucleic acids encoding a PAD polypeptide are useful in the development of antibodies directed to PAD, vaccines effective in providing protection against PRRSV infection, and diagnostic assays detecting the presence of PAD antibodies generated by a PAD-specific vaccine. The invention also discloses methods of generating antibodies to PAD, for vaccinating a pig to provide protection from PRRSV infections, a method of preparing the vaccine, a method of treating PRRSV infections in a pig, and a method of detecting antibodies to PAD of PRRSV. | 06-11-2009 |
20090155297 | Methods and Compositions for Inducing an Immune Response Against Multiple Antigens - Methods and compositions for inducing an immune response against multiple antigens are provided herein. In one aspect, the invention provides a chimeric immunogen, comprising a receptor binding domain, a translocation domain, and more than one non-contiguous heterologous antigen. In other aspects, the invention provides nucleic acids encoding chimeric immunogens of the invention, kits comprising chimeric immunogens of the invention, cells expressing chimeric immunogens of the invention, and methods or using chimeric immunogens of the invention. | 06-18-2009 |
20090155298 | Matrix Metalloproteinase 11 Vaccine - Compositions comprising matrix metalloproteinase 11 (MMP-11) or stromelysin-3 (ST-3) or the nucleic acid en->coding the MMP-11 for use in vaccines for treating tumors and cancers, which overexpress MMP-11, are described. In particular embodiments, the compositions comprise a nucleic acid encoding a fusion polypeptide that includes the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element wherein the codons encoding the MMP-11 and the immunoenhancing element have been optimized for enhanced expression of the fusion polypeptide in human cells. In other embodiments, the compositions comprise the catalytically inactivated MMP-11 linked at the C-terminus to an immunoenhancing element. The compositions can be used alone or in synergy with vaccines against other tumor associated antigens as well as with conventional therapies such as radiation therapy and chemotherapy. | 06-18-2009 |
20090169578 | TOLERIZING AGENTS - Described herein is the development of fusion proteins useful for inducing tolerance in a subject. In particular embodiments, the tolerizing agents are useful for influence autoimmune, inflammatory, and/or allergic reactions. Example tolerizing fusion proteins contain a targeting portion (which delivers the fusion protein) and a toleragen or allergen or other antigen to which tolerance is desired in a subject. In particular examples, it is demonstrated that a pσ1 fusion protein, when administered orally, facilitates systemic and mucosal tolerance. Also described is the nasal delivery of fusion proteins, for instance for restoring immunogenicity. | 07-02-2009 |
20090181046 | Capsid Proteins and Uses Therefore - The present invention provides methods for the use of viral capsid proteins and chaperone proteins to produce immunogenic macro-molecular structures as antigen carrier to carry desired epitopes or antigens, for enhancing the immunogenicity of the carried epitopes or antigens for therapeutic or prophylactic vaccination. The immunogenic macro-molecular structures may also be used for therapeutic or prophylactic vaccination. | 07-16-2009 |
20090208522 | Neutralizing Epitope-Based Growth Enhancing Vaccine - The invention provides a fusion protein comprising a plant virus coat protein and a GDF8 peptide domain, or antigenic fragment of the GDF8 peptide domain. Plant virus vectors expressing the fusion protein and methods of using these vectors are also provided. | 08-20-2009 |
20090246220 | CONSTRUCTS FOR ENHANCING IMMUNE RESPONSES - Chimeric protein constructs including a herpesvirus glycoprotein D (gD) and a heterologous polypeptide that interact with herpes virus entry mediator (HVEM) and enhance and enhance an immune response against the heterologous polypeptide and methods for their use are provided. | 10-01-2009 |
20090291098 | Immunogenic LHRH compositions and methods relating thereto - The present invention relates generally to an immunogenic LHRH composition and more particularly to an immunogenic LHRH composition comprising a LHRH C-terminal fragment of at least five amino acids. The present invention is useful, inter alia, as a prophylactic and/or therapeutic agent for the modification of fertility and behaviour patterns of animals, the achievement of livestock production gains such as increasing growth, decreasing feed conversion ratios or the control of unwanted organoleptic characteristics or the treatment of disorders of the reproductive organs. | 11-26-2009 |
20090291099 | RECOMBINANT POLYPROTEIN VACCINES FOR THE TREATMENT AND DIAGNOSIS OF LEISHMANIASIS - Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising multiple | 11-26-2009 |
20090297551 | ADJUVANT - This invention relates to a novel adjuvant comprising a transfection reagent, and to uses of this adjuvant. In particular, the adjuvant may be used in compositions for eliciting an immune response and in vaccines. | 12-03-2009 |
20090297552 | FLAGELLIN POLYPEPTIDE VACCINES - Vaccines that comprise or generate immunomodulatory flagellin polypeptides able to stimulate an innate immune response intracellularly and extracellularly employ viruses, bacteria or parasitic cells that contain expression systems for such polypeptides, as well as fusion proteins that contain antigens and/or cell penetrating peptides along with the immunomodulatory peptide. | 12-03-2009 |
20090304733 | Vaccine comprising recombinant ct or lt toxin - The present invention provides a recombinant toxin or the subunit B thereof selected from the group consisting of | 12-10-2009 |
20100040643 | FLAVIVIRUS IMMUNOGENS AND METHODS OF USE - The present invention encompasses isolated nucleic acids containing transcriptional units which encode a signal sequence of one flavivirus and an immunogenic flavivirus antigen of a second flavivirus or of a chimeric immunogenic flavivirus antigen comprising sequence from more than one flavivirus. The invention further encompasses a nucleic acid and protein vaccine and the use of the vaccine to immunize a subject against flavivirus infection. The invention also provides antigens encoded by nucleic acids of the invention, antibodies elicited in response to the antigens and use of the antigens and/or antibodies in detecting flavivirus or diagnosing flavivirus infection. | 02-18-2010 |
20100047268 | FUSION PROTEINS OF HIV REGULATORY/ACCESSORY PROTEINS - The invention relates to fusion proteins comprising the amino acid sequence of at least three HIV proteins selected from Vif, Vpr, Vpu, Rev, and Tat or derivatives of the amino acid sequence of one or more of said proteins, wherein the fusion protein is not processed to individual HIV proteins having the natural N and C termini. The invention further concerns nucleic acids encoding said proteins, vectors comprising said nucleic acids, and methods for producing said proteins. The fusion protein, nucleic acids and vectors are usable as vaccines for the at least partial prophylaxis against HIV infections. | 02-25-2010 |
20100055125 | Peptide Library - The present invention relates to a vector library comprising a multiplicity of different eukaryotic secretion vectors, wherein each vector comprises under the control of transcriptional and translational control sequences a gene encoding for an extracellular soluble fusion polypeptide which gene comprises a coding sequence for a scaffold polypeptide linked to variable coding sequences for a peptide, wherein said vectors comprise a nucleic acid coding for a secretory signal sequence linked to the gene coding for the fusion polypeptide. | 03-04-2010 |
20100062015 | FUSION PROTEIN VACCINE - The present invention relates to the fields of microbiology and vaccine technology, and concerns the development of a vaccine capable of conferring immunity to group B | 03-11-2010 |
20100092504 | COMBINED HUMAN PAPILLOMAVIRUS VLP/GENE DELIVERY SYSTEM AND USE THEREOF AS A VACCINE FOR PROPHYLAXIS AND IMMUNOTHERAPY OF INFECTIOUS DISEASES AND TUMORS - The present invention relates to compositions that contain a chimeric papillomavirus virus-like particle (VLP) in combination with a DNA molecule encoding a protein or polypeptide epitope. The chimeric papillomavirus VLP is assembled from an L1 protein or polypeptide and a chimeric protein or polypeptide containing at least a portion of the L2 protein and a protein or polypeptide including an immunogenic epitope. The composition is useful for inducing an enhanced immune response against a pathogen or a tumor. | 04-15-2010 |
20100098718 | NUCLEIC ACID VECTORS FOR IMMUNIZATION - A dimeric protein comprising a first fusion protein and a second fusion protein, wherein the first fusion protein comprises a targeting domain, a leucine zipper domain, and an antigen; and wherein the second fusion protein comprises a targeting domain, a leucine zipper domain, and optionally an antigen. Nucleic acid vectors encoding proteins of the invention are provided, particularly for use in nucleic acid vaccination. | 04-22-2010 |
20100111993 | Recombinant vaccines and use thereof - The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule. | 05-06-2010 |
20100143395 | MATERIAL WITH IMMUNOGENICITY - Provided is a fusion protein, which comprises human papillomavirus E7 antigen, virus capsid protein and molecular chaperone. Also provided is a macromolecule with immunogenicity aggregated by the fusion proteins. The particle morphology of the macromolecule is different from that of the virus-like particle. The macromolecule can be used for treatment of human papillomavirus relating diseases. | 06-10-2010 |
20100166795 | Novel Adjuvant Compounds - The invention relates to the use of bacterial cytolysin proteins, such as pneumolysin, as adjuvants for stimulating or enhancing immune responses against co-administered target antigens. Desirably, the target antigen is provided as a fusion protein with the cytolysin. The inventors have found that cytolysins may be particularly effective for stimulation of mucosal immune responses against the target antigen. | 07-01-2010 |
20100183657 | FUSION PROTEINS OF MYCOBACTERIUM TUBERCULOSIS - The present invention relates to compositions and fusion proteins containing at least two | 07-22-2010 |
20100189739 | Immunogenic compositions comprising dal/dat double mutant, auxotrophic attenuated strains of Listeria and their methods of use - The invention includes auxotrophic attenuated mutants of | 07-29-2010 |
20100196411 | Yeast-Based Vaccine for Inducing an Immune Response - The invention provided herein relates to vaccines that can be tailored to achieve a desired immune response. Some compositions provided herein are used for preferentially eliciting a humoral immune response while other compositions are useful for preferentially eliciting a cell-mediated response. Combinations of vaccine compositions are also useful for eliciting both types of responses and/or for modulating the type of immune response elicited. The invention also provides methods for eliciting an immune response in an individual by administering the compositions disclosed herein. These immune responses are useful for protecting an individual from various types of diseases, infections, and undesirable conditions. | 08-05-2010 |
20100221280 | PLANT-PRODUCED COMPOSITIONS FOR TREATING PAPILLOMAVIRUS INFECTION AND RELATED METHODS - Compositions for treating papillomavirus (PV) infection in a subject include a PV L2 polypeptide produced from a eukaryotic expression system. | 09-02-2010 |
20100255023 | DENDRITIC CELL VACCINE COMPOSITIONS AND USES OF SAME - The present invention provides adjuvants, vaccines and therapies in which antigen presentation is enhanced through inhibition of negative immune regulators. The compositions and methods are useful for generating immune responses against antigens, including microbial pathogens and tumor-associated antigens, by way of inhibiting a negative immune regulator in a cell and providing a proinflammatory stimulus. In particular, nucleotides encoding inhibitors of negative immune regulators, antigens, and co-stimulatory molecules are contacted with immune cells in order to elicit a therapeutic or prophylactic response. | 10-07-2010 |
20100260792 | RESPIRATORY SYNCYTIAL VIRUS VACCINE BASED ON CHIMERIC PAPILLOMAVIRUS VIRUS-LIKE PARTICLES OR CAPSOMERES - The present invention is directed to a chimeric papillomavirus virus-like particle (VLP) or capsomere including an L1 polypeptide and, optionally, an L2 polypeptide, and a respiratory syncytial virus (RSV) protein or polypeptide fragment thereof comprising a first epitope, where the RSV protein or polypeptide fragment thereof is attached to one or both of the L1 and L2 polypeptides. Chimeric proteins, genetic constructions, and recombinant vectors and host cells suitable for expression of the constructs and making of the chimeric VLPs or capsomeres are also disclosed. Use of the VLPs or capsomeres, or a pharmaceutical composition containing the same, is contemplated for inducing a protective immune response against RSV. | 10-14-2010 |
20100260793 | DEFENSIN-ANTIGEN FUSION PROTEINS - The present invention relates to a vaccine for increasing the immunogenicity of a tumor antigen thus allowing treatment of cancer, as well as a vaccine that increases the immunogenicity of a viral antigen, thus allowing treatment of viral infection, including immunodeficiency virus (HIV) infection. In particular, the present invention provides a fusion protein comprising a defensin fused to either a tumor antigen or viral antigen which is administered as either a protein or nucleic acid vaccine to elicit an immune response effective in treating cancer or effective in treating or preventing viral infection. | 10-14-2010 |
20100272745 | VACCINES FOR MALARIA - The present invention relates to a component for a malaria vaccine comprising: a) an immunogenic particle RTS, S and/or b) an immunogenic particle derived from the CS protein of one or more | 10-28-2010 |
20100278854 | CHLAMYDIA ANTIGENS - antigens (e.g., polypeptides, polypeptide fragments, and fusion proteins) are provided. Also provided are vaccines and pharmaceutical compositions for treating or preventing a bacterial infection, such as | 11-04-2010 |
20100285050 | Compositions and Methods - The invention relates to a composition suitable for inducing a T cell mediated immune response against an influenza virus in a vertebrate, said composition comprising nucleic acid encoding one or more epitopes of one or more internal proteins of influenza virus, wherein said composition comprises nucleic acid encoding at least two said epitopes, at least one epitope being from each of two or more internal proteins of influenza virus. The invention also relates to uses of same and to methods involving same. | 11-11-2010 |
20100285051 | VACCINE - A component for a HIV vaccine comprising:
| 11-11-2010 |
20100291134 | TRUNCATED HEPATITIS C VIRUS NS5 DOMAIN AND FUSION PROTEINS COMPRISING SAME - The invention provides truncated HCV NS5 polypeptides and fusion proteins comprising the truncated NS5 polypeptides, fused to at least one other HCV epitope derived from another region of the HCV polyprotein. The fusions can be used in methods of stimulating an immune response to HCV, for example a cellular immune response to HCV, such as activating hepatitis C virus (HCV)-specific T cells, including CD4 | 11-18-2010 |
20100297164 | Chlamydial Antigens - The invention is in the field of immunology and vaccinology. In particular, it relates to antigens derived from | 11-25-2010 |
20100303849 | Lipidated Vaccine against Dengue Virus Infection - Disclosed are immunogenic composition, fusion proteins, and related methods for inducing immune response to dengue virus infection. | 12-02-2010 |
20100310594 | RECOMBINANT ADENYLATE CYCLASE TOXIN OF BORDETELLA INDUCES T CELL RESPONSES AGAINST TUMORAL ANTIGENS - An immunogenic composition comprising a recombinant protein comprising a | 12-09-2010 |
20100316663 | Subunit Vaccine for Aquaculture - A subunit vaccine for aquaculture comprises an antigen fusion protein, and appropriate carriers or adjuvants. From amino terminal to carboxyl terminal, the antigen fusion protein comprises domain I and domain II of | 12-16-2010 |
20100322956 | METHODS AND SUBSTANCES FOR THE TREATMENT OF ALZHEIMER'S - The present invention relates to a combination of one or more nucleic acids encoding, (a) in a first open reading frame (i) a promoter, (U) an amyloid peptide, (iii) a cell surface targeting signal, (iv) a transmembrane anchoring domain and (b) in a second open reading frame (i) a group specific antigen (gag). Also the invention relates to a pharmaceutical composition and a vaccine comprising Aβ-retrop articles. | 12-23-2010 |
20100322957 | SECRETION-RELATED BACTERIAL PROTEINS FOR NLRC4 STIMULATION - Introduction of immunomodulatory T3SS polypeptides (IT3SSP's) into cells stimulates a response mediated by NLRC4 intracellularly. Introduction of said IT3SSP into the cells of a subject evoke an innate immune response in the subject. | 12-23-2010 |
20110002956 | MUTANT HUMAN CD80 AND COMPOSITIONS FOR AND METHODS OF MAKING AND USING THE SAME - Improved vaccines and methods of using the same are disclosed Immunosuppressive compositions for treating individuals who have autoimmune diseases or transplants and methods of using the same are disclosed. | 01-06-2011 |
20110008382 | Compositions and methods using recombinant MHC molecules for the treatment of uveitis - Two-domain MHC polypeptides are useful for modulating activities of antigen-specific T-cells, including for modulating pathogenic potential and effects of antigen-specific T-cells. Exemplary MHC class II-based recombinant T-cell ligands (RTLs) of the invention include covalently linked β1 and α1 domains, and MHC class I-based molecules that comprise covalently linked α1 and α2 domains. These polypeptides may also include covalently linked antigenic determinants, toxic moieties, and/or detectable labels. The disclosed polypeptides can be used to target antigen-specific T-cells, and are useful, among other things, to detect and purify antigen-specific T-cells, to induce or activate T-cells, to modulate T-cell activity, including by regulatory switching of T-cell cytokine and adhesion molecule expression, to treat conditions mediated by antigen-specific T-cells, for example autoimmune diseases or conditions such as acute and recurrent uveitis. | 01-13-2011 |
20110008383 | COMPOSITIONS OF TOLL-LIKE RECEPTOR AGONISTS AND MALARIA ANTIGENS AND METHODS OF USE - Compositions that include at least one fusion protein that includes at least a portion of at least one flagellin and at least a portion of at least one malaria antigen can be employed in methods that stimulate an immune response in a subject, in particular, sterile immunity and a protective immune response in a subject. | 01-13-2011 |
20110038888 | ADJUVANT COMPOSITIONS COMPRISING POLY-IC AND A CATIONIC POLYMER - An adjuvant composition comprising polyIC and a cationic polymer; the cationic polymer comprising from about 100 to about 500 amino acid residues, wherein the mass:mass ratio of the polyIC:cationic polymer is from about 4:1.5 to about 4:3 is described. | 02-17-2011 |
20110045013 | CAT Allergen Conjugates and Uses Thereof - The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides compositions comprising a virus-like particle (VLP) or a virus particle and at least one antigen, particularly at least one feline antigen, and more particularly at least one feline antigen that is a human allergen. In certain embodiments, the antigen is a Fel d1 antigen or a fragment thereof, covalently linked to the VLP. The invention also provides methods for producing the compositions. The compositions of the invention induce efficient immune responses, in particular antibody responses, in mammals, particularly humans. The compositions and methods of the invention are useful in the production of vaccines, in particular for the treatment and/or prevention of allergies to cat dander and other cat antigens and allergens. | 02-24-2011 |
20110070257 | Polyvalent Chimeric OSPC Vaccinogen and Diagnostic Antigen - A chimeric polyvalent recombinant protein for use as a vaccine and diagnostic for Lyme disease is provided. The chimeric protein comprises epitopes of the loop 5 region and/or the alpha helix 5 region of outer surface protein C (OspC) types. The OspC types may be associated with mammalian | 03-24-2011 |
20110076302 | Plant-derived vaccines against respiratory syncytial virus - A plant-derived vaccine against respiratory syncytial virus (RSV) is disclosed. The vaccine includes an immunogenic complex that includes plant cells transformed with a chimeric gene containing a nucleotide sequence adapted for protein expression in plants and an RSV coding sequence that encodes an antigenic protein of RSV. Also disclosed are methods of making the plant-derived vaccine of the invention, as well as transgenic plants, transgenic plant cells, and nucleic acid constructs useful in immunizing a mammal against RSV. | 03-31-2011 |
20110081369 | IMMUNE MODULATION WITH DEATH RECEPTOR-INDUCED APOPTOSIS - This invention provides chimeric proteins comprising an apoptosis-inducing molecule fused to a member of a binding pair that is capable of binding to a selected cell that expresses a death receptor. When the selected cell is exposed in vivo or ex vivo to the chimeric protein, the selected cell undergoes apoptosis. The preferred embodiment is FasL protein fused to streptavidin. The methods of using the chimeric proteins are especially beneficial in causing activated lymphocytes to undergo apoptosis, thus modulating the immune response. Patients with conditions such as asthma or allergy, or patients undergoing transplantation with allogeneic or xenogeneic tissue are examples of patients who benefit from the methods of this invention. | 04-07-2011 |
20110086058 | Immunopotentiator-Linked Oligomeric Influenza Immunogenic Compositions - Disclosed herein are immunogenic compositions for preventing infection with influenza viruses wherein the immunogenic compositions comprises an immunogen such as a hemagglutinin of an influenza virus, and an immunopotentiator such as an Fc fragment of human IgG and optionally a stabilization sequence. The immunogen is linked to the stabilization sequence which in turn is linked to the immunopotentiator. | 04-14-2011 |
20110086059 | NON-HEMOLYTIC CLYA FOR EXCRETION OF PROTEINS - The disclosure below provides a protein export system utilizing non-hemolytic variants of HlyE family member proteins for efficiently producing recombinant protein from a host cell. In a preferred embodiment, the protein export system utilizes protein export machinery endogenous to the host bacterium into which the protein export system vector is introduced. | 04-14-2011 |
20110091496 | METHODS AND COMPOSITIONS FOR THE DELIVERY OF VACCINES TO DISRUPTED EPITHELIUM - The invention features immunogenic compositions and methods useful for eliciting an immune response. In preferred embodiments, papillomavirus or adenovirus vectors are used to elicit exceptionally potent antibody and T cells responses in disrupted epithelium. The methods are useful in preventing or treating a subject having a disease or an infection. In particular examples, the methods are useful for preventing or treating a viral infection. | 04-21-2011 |
20110097355 | VIRUS-LIKE PARTICLES AS VACCINES FOR PARAMYXOVIRUS - The invention provides expression vectors and virus-like particles (VLPs) containing Newcastle Disease Virus Sequences in combination with sequences encoding proteins of interest. The vectors are useful in, for example, generating virus-like particles (VLPs) that contain proteins of interest. In one embodiment, the expressed VLPs elicit an immune response by an animal host against the protein. The invention's VLPs are useful as, for example, vaccines. | 04-28-2011 |
20110104196 | IMMUNOGENIC COMPOSITION AND METHOD OF DEVELOPING A VACCINE BASED ON FUSION PROTEIN - The present invention relates to an immunogenic composition. More particularly, the present invention is a composition directed to eliciting an immune response to HIV fusion protein. The present invention contemplates three categories of embodiments: protein or protein fragments, messenger RNA, or DNA/RNA. DNA/RNA compositions may be either naked or recombinant. The present invention further contemplates use with a variety of immune stimulants. | 05-05-2011 |
20110135678 | TOLERIZING AGENTS - Described herein is the development of fusion proteins useful for inducing tolerance in a subject. In particular embodiments, the tolerizing agents are useful for influence autoimmune, inflammatory, and/or allergic reactions. Example tolerizing fusion proteins contain a targeting portion (which delivers the fusion protein) and a toleragen or allergen or other antigen to which tolerance is desired in a subject. In particular examples, it is demonstrated that a pσ1 fusion protein, when administered orally, facilitates systemic and mucosal tolerance. Also described is the nasal delivery of fusion proteins, for instance for restoring immunogenicity. | 06-09-2011 |
20110142872 | COMPOUNDS AND METHODS FOR TREATMENT AND DIAGNOSIS OF CHLAMYDIAL INFECTION - Compounds and methods for the diagnosis and treatment of Chlamydial infection are disclosed. The compounds provided include polypeptides that contain at least one antigenic portion of a | 06-16-2011 |
20110142873 | BIOACTIVE PURIFIED HSPE7 COMPOSITIONS - A method of treating or preventing a condition related to an HPV infection is provided. The method comprises administering to a subject a composition comprising a purified Hsp65-E7 fusion protein (HspE7) admixed with an immune stimulant selected from the group consisting of CpG, a TLR3 agonist such as PolyI:C, PolyICLC, mono-phosphoryl-lipid A (MPL), MPL-trehalose 6,6′-dimycolate (MPL-TDM), and anti-CD40. A composition comprising HspE7 and one or more than one of CpG, a TLR3 agonist such as PolyI:C, PolyICLC, MPL, MPL-TDM, and anti-CD40, and method of reducing a tumor or virus development in a mammal or subject in need thereof by using the composition are also provided. | 06-16-2011 |
20110150919 | COMPOSITIONS AND METHODS FOR THE THERAPY AND DIAGNOSIS OF BREAST CANCER - Compositions and methods for the therapy and diagnosis of cancer, particularly breast cancer, are disclosed. Illustrative compositions comprise one or more breast tumor polypeptides, immunogenic portions thereof, polynucleotides that encode such polypeptides, antigen presenting cell that expresses such polypeptides, and T cells that are specific for cells expressing such polypeptides. The disclosed compositions are useful, for example, in the diagnosis, prevention and/or treatment of diseases, particularly breast cancer. | 06-23-2011 |
20110150920 | Allergy Vaccines Containing Hybrid Polypeptides - Hybrid polypeptides comprising at least two different allergenic proteins or fragments thereof wherein each fragment consists of at least eight consecutive amino acids of the respective allergenic protein are disclosed. The hybrid polypeptides and polynucleotides coding therefor can be used as pharmaceutical compositions, in particular as vaccines. | 06-23-2011 |
20110150921 | NOVEL FUSION PROTEINS AND USE THEREOF FOR PREPARING HEPATITIS C VACCINES - An immunogenic fusion protein includes at least, on the C-terminal side, a first peptide composed of the S protein deleted of the transmembrane domain thereof located at the N-terminal end thereof, of a hepatitis B virus (HBV) isolate, and on the N-terminal side, a second peptide composed of the transmembrane domain and of the ectodomain of at least one envelope protein of a hepatitis C virus (HCV) isolate. A hybrid nucleic acid molecule encoding the fusion protein, and a vector including the hybrid nucleic acid molecule, a subviral particle including the fusion protein, an immunogenic composition including at least the fusion protein, or at least the hybrid nucleic acid molecule, or at least the subviral particle, and a cell line for the production of the fusion protein, or of the hybrid nucleic acid molecule, or of the subviral particle are described. | 06-23-2011 |
20110150922 | IMMUNOGEN PLATFORM - Aspects of the present invention relate to chimeric polypeptides including HCV NS3/4A sequences and T-cell epitopes. Embodiments include nucleic acids encoding the chimeric NS3/4A polypeptides, the encoded polypeptides, compositions containing said nucleic acids, compositions containing said chimeric polypeptides, as well as methods of making and using the aforementioned compositions including, but not limited to medicaments and vaccines. | 06-23-2011 |
20110177112 | MULTI- COMPONENT L2 VACCINE FOR PREVENTION OF HUMAN PAPILLOMA VIRUS INFECTION - Embodiments of the invention are directed to methods and compositions for generating an antibody response against HPV epitopes using multi-component vaccines. One such multi-component vaccine requires a T cell helper component and a toll-like receptor (TLR) agonist. In one embodiment, the inventors described a lipopeptide composition comprising an HPV L2 epitope. | 07-21-2011 |
20110182925 | Ehrlichia canis DIVA (Differentiate Infected from Vaccinated Animals) - The invention provides | 07-28-2011 |
20110182926 | MINIGENE - The present invention provides minigenes suitable as a prophylactic or therapeutic vaccine against conditions such as cancer, infectious diseases or autoimmune diseases, and pharmaceutical compositions comprising the minigene. The minigenes of the present invention comprise (a) a human tissue plasminogen signal peptide; (b) at least one T-cell epitope; and (c) an | 07-28-2011 |
20110206715 | MOLECULAR DIFFERENCES BETWEEN SPECIES OF THE M. TUBERCULOSIS COMPLEX - Specific genetic deletion are identified in mycobacteria isolates, including variations in the | 08-25-2011 |
20110206716 | SYNERGISTIC IMMUNOGENIC FUSION PROTEIN-POLYSACCHARIDE CONJUGATE - An immunogenic composition comprising a fusion protein-polysaccharide conjugate consisting of a polysaccharide (PS) or pneumococcal bacterial cell wall polysaccharide (CWPS) conjugated to X:PdT where PdT represents the nonhemolytic variant of pneumolysin and X represents an antigenic peptide or protein of interest is provided. The immunity to X is synergistically enhanced by the fusion conjugate. Methods of protecting a subject from pneumococcal colonization or disease by administering an immunogenic composition including a fusion protein (PsaA:PdT) containing truncated PsaA and the nonhemolytic variant of pneumolysin (PdT) conjugated with CWPS (PsaA:PdT-CWPS) is also provided. | 08-25-2011 |
20110206717 | NON-TYPHOIDAL SALMONELLA VACCINES - OmpD of non-typhoidal | 08-25-2011 |
20110206718 | ANTI-FMD VACCINE COMPOSITION AND PREPARATION AND USE THEREOF - The present invention pertains to the field of immunology and genetic engineering. In particular, the present invention relates to the construction, preparation and use of a recombinant vaccine against foot-and-mouth disease virus. The vaccine comprises a tandem repeat of an antigenic epitope of FMDV VP1 protein, the constant region of the immunoglobulin heavy chain or a functional fragment thereof, and the FMDV 3D protein or an immunogenic fragment thereof. The vaccine can induce protective immune response against FMDV in an animal. | 08-25-2011 |
20110212122 | Nerve Growth Factor Conjugates and Uses Thereof - The present invention is in the fields of medicine, public health, immunology, molecular biology and virology. The invention provides composition comprising a virus-like particle (VLP) linked to at least one antigen, wherein said antigen is NGF antigen. The invention also provides a process for producing the composition. The compositions of this invention are useful in the production of vaccines, in particular, for the treatment of pain. Moreover, the compositions of the invention induce efficient immune responses, in particular antibody responses. | 09-01-2011 |
20110223187 | LIVE LISTERIA-BASED VACCINES FOR CENTRAL NERVOUS SYSTEM THERAPY - This invention is directed to methods for treating a central nervous system (CNS) tumor or cancer using live | 09-15-2011 |
20110223188 | TARGETED COSTIMULATORY POLYPEPTIDES AND METHODS OF USE TO TREAT CANCER - Compositions are provided that are targeted to tumors or tumor-associated neovasculature and enhance the function of tumor-infiltrating T cells. The compositions include fusion proteins that contain a T cell binding domain and a tumor/tumor-associated neovasculature targeting domain. The fusion proteins optionally contain a peptide/polypeptide linker domain and a domain that mediates dimerization or multimerization. The T cell binding domain can be a costimulatory molecule. Methods for using the fusion proteins to enhance an immune response are provided. Therapeutic uses for the disclosed compositions include the induction of tumor immunity. | 09-15-2011 |
20110243979 | Method of Transcutaneous Immunization Using Antigen - Transcutaneous immunization can deliver antigen to the immune system through the stratum corneum without physical or chemical penetration to the dermis layer of the skin. This delivery system induces an antigen-specific immune response. Use of skin-active adjuvants is preferred. Although perforation of intact skin is not required, superficial penetration or micropenetration of the skin can act as an enhancer; similarly, hydration may enhance the immune response. This system can induce antigen-specific immune effectors after epicutaneous application of a formulation containing one or more antigen and adjuvant. The formulation may initiate processes such as antigen uptake, processing, and presentation; Langerhans cell activation, migration from the skin to other immune organs, and differentiation to mature dendritic cells; contacting antigen with lymphocytes bearing cognate antigen receptors on the cell surface and their stimulation; and combinations thereof. Systemic and/or regional immunity may be induced; immune responses that result in prophylaxis and/or therapeutic treatments are preferred. Antigen and adjuvant activities in the formulation may be found in the same molecule, two or more different molecules dissociated from each other, or multiple molecules in a complex formed by covalent or non-covalent bonds. For antigens and adjuvants which are proteinaceous, they may be provided in the formulation as a polynucleotide for transcutaneous genetic immunization. Besides simple application of a liquid formulation, patches or other medical devices may be used to deliver antigen for immunization. | 10-06-2011 |
20110250224 | ADJUVANT COMBINATIONS OF LIPOSOMES AND MYCOBACTERIAL LIPIDS FOR IMMUNIZATION COMPOSITIONS AND VACCINES - The present invention provides a vaccine adjuvant consisting of a combination of a surfactant i.e. dimethyldeoctadecylammonium-bromide/chloride (DDA) and a lipid extract from | 10-13-2011 |
20110262478 | Recombinant Protein Bodies as Immunogen-Specific Adjuvants - An immunogen-specific is adjuvant for a vaccine or inoculum is disclosed. The adjuvant is comprised of particulate recombinant protein body-like assemblies (RPBLAs) that contain a recombinant fusion protein that contains two portions peptide-linked together. A first portion is a protein body-inducing sequence (PBIS) and a second portion is a T-cell stimulating immunogenic polypeptide whose sequence is that of a pathogenic polypeptide sequence present in or induced by a vaccine or inoculum. The adjuvant, when used as an inoculum in a host animal without a prior priming vaccination or inoculation, does not induce production of antibodies or T cell activation to the pathogenic sequence. | 10-27-2011 |
20110274711 | HLA-G POLYPEPTIDES AND PHARMACEUTICAL USES THEREOF - The present invention relates to novel proteins and pharmaceutical uses thereof The invention more specifically relates to novel proteins comprising the sequence of an HLA-5 antigen fused to the sequence of a b2 microglobulin. The invention also relates to methods of producing such polypeptides, pharmaceutical compositions comprising the same, as well as their uses for treating various diseases including organ/tissue rejection. | 11-10-2011 |
20110280902 | COMPOUNDS AND METHODS FOR DIAGNOSIS AND TREATMENT OF LEISHMANIASIS - Compounds and methods are provided for diagnosing, preventing, treating and detecting leishmaniasis infection and stimulating immune responses in patients are disclosed. The compounds disclosed are include polypeptides and fusion proteins that contain at least one immunogenic portion of one or more | 11-17-2011 |
20110300172 | FUSION PROTEINS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS FOR TREATMENT AND/OR PREVENTION OF ATHEROSCLEROSIS - A fusion protein comprising an antigenic fragment of apoB-100 and a suitable carrier and related compositions methods and systems. | 12-08-2011 |
20110318379 | Vaccine for Porcine Post-Weaning Diarrhea Caused by Enterotoxigenic Escherichia Coli - Vaccines and methods for making and using the same. An example vaccine may be a vaccine against enterotoxigenic | 12-29-2011 |
20120009211 | BIMER OR AN OLIGOMER OF A DIMER, TRIMER, QUADROMER OR PENTAMER OF RECOMBINANT FUSION PROTEINS - The invention relates to oligomers of a dimer, trimer, quatromer or pentamer of recombinant fusion proteins. Said oligomers are characterized in that the recombinant fusion proteins have at least one component A and at least one component B, whereby component A contains a protein or a protein segment with a biological function, in particular with a ligand function for antibodies, for soluble or membranous signal molecules, for receptors or an antibody, or an antibody segment, and component B contains a protein or a protein segment which dimerizes or oligomerizes the dimer, trimer, quatromer or pentamer of the recombinant fusion protein, without the action of third-party molecules. The invention also relates to the use of dimers or oligomers of this type for producing a medicament, to the fusion proteins which cluster in dimers or oligomers and to their DNA sequence and expression vectors or host cells comprising this DNA sequence. | 01-12-2012 |
20120014984 | COMPOSITIONS AND METHODS FOR PREVENTION OF ESCAPE MUTATION IN THE TREATMENT OF HER2/NEU OVER-EXPRESSING TUMORS - This invention provides compositions and methods for treating and vaccinating against an Her2/neu antigen-expressing tumor and inducing an immune response against dominant in a non-human animal. | 01-19-2012 |
20120020992 | Production of Biologically Active Proteins - A fusion protein that is expressed in a recombinant protein body-like assembly (RPBLA) in host eukaryotic cells and organisms is disclosed. More particularly, a biologically active polypeptide fused to a protein sequence that mediates the induction of RPBLA formation is expressed and accumulated in host cells after transformation with an appropriate vector. The eukaryotic host cell does not produce protein bodies in the absence of the fusion protein. Methods for preparing and using the RPBLAs and the fusion protein are also disclosed, as are nucleic acid molecules that encode the fusion proteins. | 01-26-2012 |
20120064106 | FLAGELLIN FUSION PROTEINS AND USE THEREOF TO INDUCE IMMUNE RESPONSES AGAINST PSEUDOMONAS AERUGINOSA - The invention provides compositions and fusion proteins comprising a flagellin adjuvant and a | 03-15-2012 |
20120107343 | PRODUCTION OF RECOMBINANT PROTEINS IN CILIATES AND USES THEREOF - This invention is directed to methods for recombinant polypeptide production and, in particular, methods and products for the production and purification of recombinant proteins in ciliates. | 05-03-2012 |
20120114688 | VACCINES COMPRISING NON-SPECIFIC NUCLEOSIDE HYDROLASE AND STEROL 24-C-METHYLTRANSFERASE (SMT) POLYPEPTIDES FOR THE TREATMENT AND DIAGNOSIS OF LEISHMANIASIS - Compositions and methods for preventing, treating and detecting leishmaniasis are disclosed. The compositions generally comprise fusion polypeptides comprising | 05-10-2012 |
20120121640 | OX40/TRAIL Fusion Proteins - Fusion proteins which act on the OX40/TRAIL signaling axes are provided. The proteins are useful in the treatment or amelioration of autoimmune diseases, particularly multiple sclerosis, and alloimmune diseases, as well as cancer. | 05-17-2012 |
20120128710 | Enhancement of Pathogen-Specific Memory Th17 Cell Responses - Compositions and methods for enhancing Th1/Th17 cell responses and decreasing Th2 cell responses are disclosed herein. In various embodiments the present invention describes activation of human dendritic cells and enhancement of antigen-specific T cell responses in a Dectin-1-expressing human dendritic cells comprising an anti-Dectin-1-specific antibody or fragment thereof fused with one or more antigens. TLR2 ligands may also be included to enhance the activation and for enhancement of T-cell responses. Further, the invention also includes methods based on the compositions described herein for the treatment of pathogenic infections. | 05-24-2012 |
20120135028 | VACCINE - The present disclosure provides immunogenic compositions that include at least two paramyxovirus F protein antigens selected from human metapnuemovirus (hMPV), paarainfluenza virus (PIV) and respiratory syncytial virus (RSV). The antigens of the disclosed compositions are recombinant F protein polypeptides, which have been modified to stabilize the trimeric prefusion conformation. Nucleic acids encoding the antigens, as well as methods for their production and use are also provided. | 05-31-2012 |
20120156237 | Novel Antitoxin and Vaccine Platform Based on Nodavirus VLPS - Antitoxin and vaccine compositions based on nodavirus VLPs are provided. Anthrax antitoxin and vaccine compositions are provided. Methods of treating toxins with VLP-based antitoxins are provided. Methods of raising an immune response with immunogen decorated VLPs are provided. | 06-21-2012 |
20120164168 | B7-DC VARIANTS IMMUNOGENIC COMPOSITIONS AND METHODS OF USE THEREOF - Compositions and methods for costimulating T cells (i.e., increasing antigen-specific proliferation of T cells, enhancing cytokine production by T cells, stimulating differentiation ad effector functions of T cells and/or promoting T cell survival) are provided. Suitable compositions include variant B7-DC polypeptides, fragments and fusion proteins thereof. Variant B7-DC polypeptides have reduced binding affinity for the inhibitory PD-1 ligand and substantially retain the ability to costimulate T cells. Methods for using variant B7-DC polypeptides to stimulate immune responses in subjects in need thereof are provided. | 06-28-2012 |
20120201845 | TRANSCUTANEOUS IMMUNIZATION WITHOUT HETEROLOGOUS ADJUVANT - Transcutaneous immunization can deliver antigen to the immune system through the stratum corneum without physical or chemical penetration to the dermis layer of the skin. This delivery system induces an antigen-specific immune response without the use of a heterologous adjuvant. This system can induce antigen-specific immune effectors after epicutaneous application of a formulation containing one or more antigens Immune responses that provide prophylactic and/or therapeutic treatments are preferred. Antigenic activities in the formulation may be found in the same molecule, two or more different molecules dissociated from each other, or multiple molecules in a complex formed by covalent or non-covalent bonds. For antigens which are proteinaceous, they may be provided in the formulation as a polynucleotide for transcutaneous genetic immunization. Besides simple application of a dry or liquid formulation to the skin, patches and other medical devices may be used to deliver antigen for immunization. | 08-09-2012 |
20120201846 | POLYMER PARTICLES AND USES THEREOF - The present invention relates to polymer particles and uses thereof. In particular the present invention relates to functionalised polymer particles, processes of production and uses thereof in eliciting a cell-mediated immune response and in the treatment or prevention of diseases or conditions including those caused by intracellular pathogens. | 08-09-2012 |
20120219579 | VIRUS LIKE PARTICLES COMPRISING TARGET PROTEINS FUSED TO PLANT VIRAL COAT PROTEINS - Virus like particles comprising a fusion protein and substantially free of nucleic acid, wherein the fusion protein comprises a plant viral coat protein and a target protein, are provided. Immunogenic compositions comprising the virus like particles can be administered to subjects to induce protective immune responses in the subjects. Methods of producing the virus like particles are also provided. | 08-30-2012 |
20120219580 | HIGHLY PATHOGENIC AVIAN INFLUENZA VIRUS PROTEIN VACCINE DERIVED FROM TRANSGENIC PLANT, AND PREPARING METHOD THEREOF - The present invention relates to a method for producing transgenic plants, which involves producing hemagglutinin proteins of the H5N1 virus using a plant transformation recombinant vector, wherein said vector can express hemagglutinin proteins of the H5N1 virus, the highly pathogenic avian influenza virus, and transport proteins expressed in plants to the endoplasmic reticulum and enable the retention of the proteins in the endoplasmic reticulum to enable glycosylation required for antigen activity. The present invention also relates to a method for the mass production of hemagglutinin proteins of the antigenic H5N1 virus from transgenic plants or a vaccine composition for the avian influenza virus comprising the transgenic plants or the hemagglutinin proteins produced from the plants. The transgenic plants can be used as edible vaccines, antigenic hemagglutinin proteins produced can be used as protein vaccines for the H5N1 avian influenza virus, or as diagnostic reagents for avian influenza virus infection. | 08-30-2012 |
20120231030 | MULTI-EPITOPIC VACCINE - The present invention relates to isolated polypeptides comprising: (i) a protein transduction domain consisting of ZEBRA or a fragment thereof that retains the capacity of internalization, (ii) at least one CD4 | 09-13-2012 |
20120237539 | METHOD FOR MAKING TARGETED THERAPEUTIC AGENTS DIRECTED TO SOLUBLE TARGETS - Provided herein are methods for making targeted therapeutics that target soluble agents such as toxins, venoms, and factors that alter physiological biopathways as well as methods of using such therapeutics to treat patients or patient populations to reduce, eliminate, or inactivate, detrimental soluble agents that such patients or patient populations have been exposed to. In several embodiments the targeted therapeutics comprise a portion that interacts with a soluble agent of interest and a second portion that interacts with a subject's immune system, which enables treatment of a patient for exposure to the soluble agent. | 09-20-2012 |
20120258129 | MYCOBACTERIUM TUBERCULOSIS FUSION PROTEIN AND USES THEREOF - The present invention is related to a | 10-11-2012 |
20120263747 | Albumin-Fused Anti-Angiogenesis Peptides - The invention relates to proteins comprising angiogenesis inhibiting peptides, such as endostatin peptides (including, but not limited to, fragments and variants thereof), which exhibit anti-retroviral activity, fused or conjugated to albumin (including, but not limited to fragments or variants of albumin). These fusion proteins are herein collectively referred to as ‘albumin fusion proteins of the invention.’ These fusion proteins are herein collectively referred to as ‘albumin fusion proteins of the invention.’ These fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The invention encompasses therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits. The invention also encompasses nucleic acid molecules encoding the albumin fusion proteins of the invention, as well as vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins of the invention using these nucleic acids, vectors, and/or host cells. The invention also relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor aniogenesis induced cell fusion. The invention further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinophathy, progressive macular degeneration or rheumatoid arthritis. | 10-18-2012 |
20120263748 | Superior Molecular Vaccine Linking the Translocation Domain of a Bacterial Toxin to an Antigen - Nucleic acids encoding a chimeric or fusion polypeptide which polypeptide comprises a first domain comprising a translocation polypeptide; and a second domain comprising at least one antigenic peptide are disclosed. The preferred translocation polypeptide is a bacterial toxin translocation polypeptide, such as domain II of | 10-18-2012 |
20120269844 | VACCINES FOR THE TREATMENT OF NEOPLASIAS FROM VIRAL CAPSIDS OF BIRNAVIRUS CONTAINING ANTIGENS OF THE HUMAN PAPILLOMAVIRUS - The invention relates to therapeutic vaccines for the treatment of neoplasias caused by the human papillomavirus (HPV). In particular, the vaccines of the present invention are formed by chimeric virus-like capsids of birnavirus containing papillomavirus antigens. | 10-25-2012 |
20120276132 | Atoxic recombinant holotoxins of Clostridium difficile as immunogens | 11-01-2012 |
20120282291 | VACCINE VECTORS AND METHODS OF ENHANCING IMMUNE RESPONSES - Provided herein are vaccine vectors including an antigenic polypeptide and an HMGB1 polypeptide present on the surface of the vaccine vector. Compositions comprising the vaccine vectors are also provided and include a pharmaceutically acceptable carrier, suitably a carrier for oral or nasal administration. Also provided are methods of enhancing immune responses, in particular antibody immune response and suitably an IgA response, by administering the vaccine vectors or compositions disclosed herein to a subject. | 11-08-2012 |
20120294883 | OLIGOMERIC RECEPTOR LIGAND PAIR MEMBER COMPLEXES - This invention concerns an oligomeric receptor-ligand pair member complex in general and an oligomeric MHC-peptide complex in particular and a method of labeling, detecting and separating mammalian T cells according to the specificity of their antigen receptor by use of the oligomer. The invention further concerns a method of targeting the oligomeric receptor-ligand pair member complexes to target molecules of the surface of a target cell in order to present antigens on the target cell. The invention further concerns related pharmaceutical and diagnostic compositions and processes. | 11-22-2012 |
20120294884 | METHODS OF BLOCKING TISSUE DESTRUCTION BY AUTOREACTIVE T CELLS - Methods for blocking autoreactive T cell-initiated destruction of tissues in a mammal are provided. In one embodiment, the method comprises administering a purified CD24 polypeptide, a fusion protein comprising such polypeptide, or a biologically active fragment of such polypeptide to a mammalian subject who is suspected of having or predisposed to having an autoimmune disease. In another embodiment, anti-CD24 antibody or anti-CD24 Fab fragments are administered to the subject. In another embodiment, the method comprises administering a CD24 antisense molecule, an expression vector encoding a CD24 antisense molecule, CD24 dsRNAi, or an expression vector encoding CD24 dsRNAi to the subject. The present invention also relates to isolated and purified CD24 fusion proteins employed in the present methods and to transgenic mice that express the human CD24 protein on their T cells and/or their vascular endothelial cells but do not express murine heat shock antigen on any cells. | 11-22-2012 |
20120315293 | Antigen Delivery Vectors and Constructs - The present invention relates to fluorocarbon vectors for the delivery of antigens to immunoresponsive target cells. It further relates to fluorocarbon vector-antigen constructs and the use of such vectors associated with antigens as vaccines and immunotherapeutics in animals. | 12-13-2012 |
20130011429 | IMMUNOGENIC COMPOSITION - Immunogenic compositions and methods of their use, as well as processes for their production are provided herein. | 01-10-2013 |
20130034578 | RECOMBINANT MULTIMERIC INFLUENZA PROTEINS - The invention relates to immunogenic compositions comprising recombinant multimeric influenza proteins or parts thereof fused to a streptavidin affinity tag, preferably recombinant trimeric influenza virus hemagglutinin and/or recombinant tetrameric influenza virus neuraminidase, or vectors comprising nucleic acid sequences encoding such influenza proteins. The inventions further relate to methods for the preparation of such immunogenic compositions and uses thereof and methods for eliciting an immune response in an individual. | 02-07-2013 |
20130039938 | HIGHLY EFFICIENT INFLUENZA MATRIX (M1) PROTEINS - This invention discloses a method of increasing production of virus-like particles comprising expressing an avian influenza matrix protein. The invention also comprises methods of making and using said VLPs. | 02-14-2013 |
20130052217 | TUMOR VACCINATION INVOLVING A HUMORAL IMMUNE RESPONSE AGAINST SELF-PROTEINS - The present invention relates to tumor immunotherapy, in particular to tumor vaccination, using chimeric proteins comprising all or a portion of a hepatitis B virus core antigen protein and an amino acid sequence comprising an epitope derived from the extracellular portion of a tumor-associated antigen. In particular, the present invention provides virus-like particles comprising said chimeric proteins, which are useful for eliciting a humoral immune response in a subject against the tumor-associated antigen, in particular against cells carrying said tumor-associated antigen on their surface, wherein the tumor-associated antigen is a self-protein in said subject. | 02-28-2013 |
20130058968 | PISCINE REOVIRUS IMMUNOGENIC COMPOSITIONS - The invention is directed to immunogenic compositions and methods for inducing an immune response against Piscine reoviruses in an animal. In another aspect, the invention relates to antibodies that bind Piscine reovirus poplypeptides. In yet another aspect, the invention relates to methods for preventing, or reducing PRV infection in an animal. | 03-07-2013 |
20130058969 | CHLOROPLASTS ENGINEERED TO EXPRESS PHARMACEUTICAL PROTEINS - Vaccines for conferring immunity in mammals to infective pathogens are provided, as well as vectors and methods for plastid transformation of plants to produce protective antigens and vaccines for oral delivery. The vaccines are operative by parenteral administration as well. The invention also extends to the transformed plants, plant parts, and seeds and progeny thereof. The invention is applicable to monocot and dicot plants. | 03-07-2013 |
20130071424 | PEPTIDES MIMICKING HIV-1 VIRAL EPITOPES IN THE V2 LOOP FOR THE GP120 SURFACE ENVELOPE GLYCOPROTEIN - The present invention relates to an isolated immunogenic peptide comprising a V2 loop fragment from HIV surface envelope glycoprotein gp120. This peptide binds specifically with antibodies in blood of patients vaccinated with a vaccine that has shown protection from HIV-1 infection, does not react with blood of matched patients who did not receive the vaccine, and can, therefore, elicit anti-HIV-1 antibodies which protect against HIV-1 infection. Other aspects of the present invention relate to an isolated immunogenic polypeptide comprising the peptide inserted into an immunogenic scaffold protein, a vaccine composition comprised of the immunogenic peptide and an immunologically or pharmaceutically acceptable vehicle or excipient as well as methods of inducing an immune response against HIV-1 and methods of detecting HIV-1. | 03-21-2013 |
20130095133 | PHARMACEUTICAL COMPOSITIONS COMPRISING A POLYPEPTIDE COMPRISING AT LEAST ONE CXXC MOTIF AND HETEROLOGOUS ANTIGENS AND USES THEREOF - The invention relates to pharmaceutical compositions using a polypeptide comprising at least one CXXC motif, such as | 04-18-2013 |
20130108661 | METHODS AND COMPOSITIONS FOR CANCER IMMUNOTHERAPY USING FLAGELLIN-TUMOR ASSOCIATED ANTIGEN FUSION PROTEIN EXPRESSING TUMOR CELLS | 05-02-2013 |
20130115239 | PROSTATE CANCER DNA VACCINE - The present invention concerns an (adjuvant) treatment or prevention option for the treatment and prevention of prostate cancer. In particular, it pertains to the provision of recombinant, optimized PAP genes which are useful as DNA vaccines for the above treatment or prevention. | 05-09-2013 |
20130115240 | RECOMBINANT BCG STRAINS WITH ENHANCED ABILITY TO INHIBIT INTRACELLULAR MYCOBACTERIAL GROWTH - A recombinant bacterial cell strain is disclosed. It comprises: a) a first vector comprising a fusion transgene encoding Ag85B-CFP10 fusion protein, the fusion transgene being operably linked to a promoter effective for expression of the Ag85B-CFP10 fusion protein; and b) a second vector comprising a transgene encoding interleukin-12 (IL-12), the transgene being operably linked to a promoter effective for expression of the IL-12 protein. A method of inhibiting intracellular growth of | 05-09-2013 |
20130115241 | MICROVESICLES DERIVED FROM CELL PROTOPLAST AND USE THEREOF - The present application relates to microvesicles derived from a protoplast which is a bacterial, arhaea, fungal or plant cell or the like from which a cell wall is removed. The microvesicles derived from a protoplast enables free loading of a material necessary for diagnosis, treatment, vaccine, target induction, cell membrane fusion with a target cell, reduction of in vivo and in vitro side effects, stability improvement, and the like, and allows the therapeutic material, the diagnostic material and/or the vaccine material to be delivered specifically to a specific tissue or cell. | 05-09-2013 |
20130129768 | TREATMENT OR PREVENTION OF INFECTION - The invention relates to a method of reducing the incidence or severity of a disease or condition in a subject, said disease or condition being one associated with the presence of a microbial pathogen in an oral tissue of a subject, and including the use of a composition forming an anti-microbial and an immunogen against a microbial pathogen. | 05-23-2013 |
20130129769 | METHOD FOR MAKING TARGETED THERAPEUTIC AGENTS DIRECTED TO SOLUBLE TARGETS - Provided herein are methods for making targeted therapeutics that target soluble agents such as toxins, venoms, and factors that alter physiological biopathways as well as methods of using such therapeutics to treat patients or patient populations to reduce, eliminate, or inactivate, detrimental soluble agents that such patients or patient populations have been exposed to. In several embodiments the targeted therapeutics comprise a portion that interacts with a soluble agent of interest and a second portion that interacts with a subject's immune system, which enables treatment of a patient for exposure to the soluble agent. | 05-23-2013 |
20130129770 | INFLUENZA VACCINE - The present invention relates to a composition comprising at least one ISCOM complex and at least one ectodomain from at least one hemagglutinin (HA) domain and at least one ectodomain from at least one neuraminidase (NA) domain from one or more influenza virus, wherein the extodomains represent ectodomains isolated from the influenza virus. The invention also regards a kit. The composition may be used as an immune stimulating medicine, immune modulating pharmaceutical or a vaccine e.g. against influenza for vertebrates, e.g. birds and mammals. | 05-23-2013 |
20130136763 | Methods Of Treatment With Compositions That Include Hemagglutinin - Methods that stimulate a protective immune response in a subject include a portion of a protein from a naturally occurring viral hemagglutinin, wherein the protein portion includes at least a portion of a globular head and at least a portion of at least one secondary structure that causes the globular head to essentially retain its tertiary structure, and wherein the protein portion lacks a transmembrane domain, a cytoplasmic domain and an HA2 subunit. Compositions administered to the subject can further include a carrier and can be administered in single or multiple doses. | 05-30-2013 |
20130149328 | PLANT-DERIVED CHOLERA AND MALARIA VACCINE - Described herein are methods for simultaneously immunizing a subject against Cholera and Malarial infection. Specifically exemplified herein are methods that involve administering compositions comprising a CTB-AMA1 or CTB-MSP1 derived from plants having plastids transformed to express such conjugates. | 06-13-2013 |
20130149329 | BROADLY PROTECTIVE SHIGELLA VACCINE BASED ON TYPE III SECRETION APPARATUS PROTEINS - Broad-based, cross-protective, O-serotype independent vaccines against | 06-13-2013 |
20130149330 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF BLOCKING BACILLUS ANTHRACIS - The present invention is directed to novel pharmaceutical compositions and methods of inhibiting or blocking one or more virulence antigenic factors of multiple strains of | 06-13-2013 |
20130171185 | NOROVIRUS DERIVED IMMUNOGENIC COMPOSITIONS AND METHODS - The invention relates to chimeric norovirus VP1 proteins containing the S-domain of VP1 of a first norovirus strain and a P-domain that contains at least a portion of the P-domain of VP1 of a second norovirus strain. The invention also relates to nucleic acids that encode the chimeric VP1 proteins, virus-like particles that contain a chimeric norovirus VP1 protein, and to immunogenic compositions. | 07-04-2013 |
20130177585 | PAPILLOMAVIRUS L2 N-TERMINAL PEPTIDES FOR THE INDUCTION OF BROADLY CROSS-NEUTRALIZING ANTIBODIES - The invention comprises a method for inducing broadly cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types or against heterologous papillomavirus types in humans comprising administering to a human in need thereof an immunogenic peptide or protein (or polynucleotide encoding therefor), where the immunogenic peptide or protein is: (a) a peptide or protein of at least 10 amino acid residues in length having a sequence corresponding to either a sequence from the N terminal amino acids 1-200 of papillomavirus L2 protein (for cross-neutralizing antibodies against cutaneous and mucosal papillomavirus types) or a sequence from the N terminal amino acids 1-88 of papillomavirus L2 protein (for cross-neutralizing antibodies against heterologous papillomavirus types), (b) a peptide or protein of at least 10 amino acid residues in length with at least 55% identity with the sequence from (a), or (c) a peptide or protein as defined in either (a) or (b) which is conjugated or fused to a protein or peptide other than a papillomavirus L2 protein or peptide. | 07-11-2013 |
20130177586 | MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF IDENTIFYING AGENTS THAT MODULATE MYC - Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response. | 07-11-2013 |
20130177587 | FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS) - Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics. | 07-11-2013 |
20130183333 | INDUCED ACTIVATION IN DENDRITIC CELLS - The present invention is directed to a composition and method which to treat diseases and to enhance a regulated immune response. More particularly, the present invention is drawn to compositions that are based on dendritic cells modified to express an inducible form of a co-stimulatory polypeptide. | 07-18-2013 |
20130195908 | Molecular Complex for Targeting Antigens Towards Cells Comprising Antigens and Uses Thereof for Vaccination - The invention relates to a molecular complex for targeting the antigen towards cells comprising antigens, including at least one antigen associated with at least two ligands of surface molecules of cells comprising antigens, said complex including at least one first ligand of a sulphated sugar of the glycosaminoglycan family and a second ligand of a specific surface molecule of cells comprising antigens, and said first ligand being covalently bonded with said antigen and/or said second ligand. | 08-01-2013 |
20130195909 | Composite Antigenic Sequences and Vaccines - The invention relates to composite antigens comprising a peptide with contiguous amino acid sequence derived from a plurality of antigenic epitopes of one or more pathogens that induces an immune response in a mammal that is protective against infection by the one or more pathogens. In addition, the invention relates to vaccines comprising composite antigens and to method for treating and preventing an infection. | 08-01-2013 |
20130202635 | PEPTIDE VACCINES AGAINST GROUP A STREPTOCOCCI - This invention, in one aspect, relates to synthetic immunoreactive peptides. These peptides are approximately 20-25 amino acids in length which are portions of the N termini of the M proteins of the most prevalent United States (U.S.) Group A | 08-08-2013 |
20130202636 | Compositions and Methods for Topical Application and Transdermal Delivery of Botulinum Toxins - A composition for topical application of a botulinum toxin (including botulinum toxin derivatives) comprises a botulinum toxin and a carrier comprising a polymeric backbone comprising a long-chain polypeptide or nonpeptidyl polymer having attached positively charged branching or “efficiency” groups. The invention also relates to methods for reducing muscle paralysis and other conditions that may be treated with a botulinum toxin, particularly paralysis of subcutaneous, and most particularly, facial, muscles, by topically applying an effective amount of the botulinum toxin and carrier, in conjunction, to the subject's skin or epithelium. Kits for administration are also described. | 08-08-2013 |
20130243808 | COMPOSITIONS AND METHODS FOR VACCINATING HUMANS AND ANIMALS AGAINST ENVELOPED VIRUSES - Immunogenic compositions and methods for vaccinating humans and animals against enveloped viruses, and more particularly against influenza viruses. Immunogenic compositions are composed of internal moieties of an enveloped virus. Such internal moieties are more highly conserved between different viral strains than are their external moiety counterparts. Consequently, these immunogenic compositions have an increased likelihood of generating immuno-protective responses in humans and animals against enveloped viruses that are strain independent. Methods are also disclosed that increase the ability of the immunogenic compositions to generate immuno-protective responses against their target viruses. | 09-19-2013 |
20130243809 | RECOMBINANT FLAVIVIRAL CONSTRUCTS AND USES THEREOF - A recombinant viral construct for expressing an exogenous polypeptide in a cell and uses thereof are provided. The recombinant viral constructs are derived from Japanese encephalitis virus (JEV). The recombinant viral constructs encodes a fusion protein, which includes an exogenous (i.e., non-JEV) polypeptide and a JEV non-structural protein 1 (JEV NS1) or a segment thereof. Particularly, the exogenous polypeptide is inserted into the carboxyl-terminus of the JEV NS1, and the production of the recombinant fusion protein does not affect viral replication. Upon infection a cell with such recombinant viral constructs, JEV particles comprising limited multiplicative virions (LMV) may be produced. Each LMV comprises the as-described JEV replicon. The JEV particles are useful in eliciting an immune response to the exogenous polypeptide in a host and thereby confer the host with protective immunization against the exogenous polypeptide. | 09-19-2013 |
20130243810 | SYNERGISTIC IMMUNOGENIC COMPOSITIONS BASED ON PROTEIN ANTIGENS COMBINED WITH PERTUSSIS CELL ANTIGEN AND INACTIVATED TOXINS - The present invention relates to synergistic immunogenic compositions for preventing whooping cough and infections caused by | 09-19-2013 |
20130259891 | USE OF LISTERIA VACCINE VECTORS TO REVERSE VACCINE UNRESPONSIVENESS IN PARASITICALLY INFECTED INDIVIDUALS - This invention relates to methods of using a | 10-03-2013 |
20130266608 | METHODS AND COMPOSITIONS TO PRODUCE VACCINES AGAINST SMALLPOX IN PLANTS - Compositions and methods for producing plant-derived immunogenic compositions that confer immunity against smallpox in a subject are provided. Plants engineered to produce antigenic proteins as well as expression cassettes comprising nucleic acids encoding proteins thereof are described. Methods of immunizing subjects with plant-derived compositions are also provided. | 10-10-2013 |
20130287810 | VACCINE COMPOSITIONS AND USES THEREOF - The present invention relates to vaccine compositions and uses thereof. Embodiments of the present invention provide oral bacterial (e.g., probiotic lactic acid bacteria) vaccine delivery systems comprising an antigen and a dendritic cell-targeting peptide. Such compositions target vaccines to dendritic cells, resulting in a high level of humoral and acquired immunity, including both mucosal and systemic immunity. Such delivery systems find use in the specific delivery of a wide variety of oral vaccines to subjects. | 10-31-2013 |
20130295128 | CHIMERIC VACCINES - The invention provides chimeric proteins and nucleic acids encoding these which can be used to generate vaccines against selected antigens. In one aspect, a chimeric protein comprises an antigen sequence and a domain for trafficking the protein to an endosomal compartment, irrespective of whether the antigen is derived from a membrane or non-membrane protein. In one preferred aspect, the trafficking domain comprises a lumenal domain of a LAMP polypeptide. Alternatively, or additionally, the chimeric protein comprises a trafficking domain of an endocytic receptor (e.g., such as DEC-205 or gp200-MR6). The vaccines (DNA, RNA or protein) can be used to modulate or enhance an immune response against any kind of antigen. In one preferred aspect, the invention provides a method for treating a patient with cancer by providing a chimeric protein comprising a cancer-specific antigen or a nucleic acid encoding the protein to the patient. | 11-07-2013 |
20130309265 | Yeast-Based Therapeutic for Chronic Hepatitis C Infection - Disclosed are compositions, including vaccines, and methods for vaccinating an animal against hepatitis C virus (HCV) and for treating or preventing hepatitis C viral infection in an animal. The invention includes a variety of novel HCV fusion proteins that can be used directly as a vaccine or in conjunction with a yeast-based vaccine vehicle to elicit an immune response against HCV in an animal. The invention also includes the use of the HCV fusion gene and protein described herein in any diagnostic or therapeutic protocol for the detection and/or treatment or prevention of HCV infection. | 11-21-2013 |
20130344099 | FUSION PROTEIN FOR SECRETORY PROTEIN EXPRESSION - There is provided a fusion protein suitable for secretion of more than one polypeptide(s) of interest (POI) comprising a signal peptide, a POI, a passenger domain comprising a beta stem domain from an autotransporter protein, and a translocator domain from an autotransporter protein, wherein the beta stem-forming sequence of the passenger domain is essentially intact and the POI(s) is/are fused to the beta stem domain. | 12-26-2013 |
20130344100 | VIRUS LIKE PARTICLE PRODUCTION IN PLANTS - A method of producing a virus like particle (VLP) in a plant, and compositions comprising VLPs, are provided. The method involves introducing a nucleic acid comprising a regulatory region active in the plant and operatively linked to a chimeric nucleotide sequence encoding, in series, an ectodomain from a virus trimeric surface protein or fragment thereof, fused to an influenza transmembrane domain and cytoplasmic tail, into the plant, or portion of the plant, the ectodomain is from a non-influenza virus trimeric surface protein and heterologous with respect to the influenza transmembrane domain, and the cytoplasmic tail. The plant or portion of the plant are incubated under conditions that permit the expression of the nucleic acid, thereby producing the VLP. A VLP produced by this method are also provided. | 12-26-2013 |
20130344101 | B7-1-PE40KDEL EXOTOXIN FUSION GENE-BASED DNA VACCINE AND THE USE THEREOF - The present invention relates to the fields of immunology and molecular biology and related to a B7-1-PE40KDEL exotoxin fusion gene-based DNA vaccine and the use thereof. Specifically, the DNA vaccine contains a recombinant expression vector, and the vector contains exotoxin fusion gene B7-1-PE40KDEL, which is effectively ligated into selected eukaryotic expression vectors, such as pcDNA3.1/Zeo(+), pWLNEO, pSV2CAT, pOG44, pXT1, pSG, pSVK3, pBPV, pMSG, pSVL, and adenovirus. The invention also relates to the exotoxin fusion gene B7-1-PE40KDEL, the encoded exotoxin fusion protein, a recombinant expression vector that contains the exotoxin fusion gene, and compositions that contain the recombinant expression vector. The DNA vaccine in this invention has a good effect on the treatment or prevention of allogeneic tissue/organ transplant rejection and hematopoietic stem cell transplantation rejection such as GVHD. | 12-26-2013 |
20140010837 | Methods and Compositions for Preventing a Condition - Provided herein are methods, compositions, and kits for preventing, inhibiting, reducing the severity of, or treating a disease or condition. A pharmaceutical composition provided herein can comprise a nucleic acid sequence encoding an antigen fused to an immune cell product, e.g., MIP-3α, and an adjuvant. The antigen can be from a bacteria, virus, fungus, parasite, or cancer. The antigen can be an Alzheimer's disease antigen. | 01-09-2014 |
20140017272 | TRANSGENIC ALGAE FOR DELIVERING ANTIGENS TO AN ANIMAL - Delivery systems and methods are provided for delivering a biologically active protein to a host animal. The systems and methods provided include obtaining an algal cell transformed by an expression vector, the expression vector comprising a nucleotide sequence coding for the biologically active protein, operably linked to a promoter. In one illustrated embodiment, the biologically active protein is an antigenic epitope and upon administration to the animal the algal cell induces an immune response in the host animal. | 01-16-2014 |
20140017273 | Albumin-Fused Anti-Angiogenesis Peptides - The present disclosure relates to albumin fusion protein including an angiogenesis inhibiting peptide, or a fragment or variant thereof, and albumin, or a fragment or variant thereof. The fusion proteins exhibit extended shelf-life and/or extended or therapeutic activity in solution. The disclosure includes therapeutic albumin fusion proteins, compositions, pharmaceutical compositions, formulations and kits, as well as nucleic acid molecules encoding the albumin fusion proteins, vectors containing these nucleic acids, host cells transformed with these nucleic acids and vectors, and methods of making the albumin fusion proteins using these nucleic acids, vectors, and/or host cells. The disclosure further relates to compositions and methods for inhibiting proliferation of vascular endothelial cells and tumor angiogenesis induced cell fusion. The disclosure further relates to compositions and methods preventing growth of, or promoting regression of, primary tumors and metastases; and for treating cancer, diabetic retinophathy, progressive macular degeneration or rheumatoid arthritis. | 01-16-2014 |
20140037672 | FUSION PROTEINS COMPRISING ANTIGENIC APOB-100 PROTEIN FRAGMENTS AND A PROTEIN CARRIER, RELATED COMPOSITIONS, METHODS AND SYSTEMS FOR TREATMENT AND/OR PREVENTION OF ATHEROSCLEROSIS - A fusion protein comprising an antigenic fragment of apoB-100 and a suitable carrier and related compositions methods and systems. | 02-06-2014 |
20140093532 | Immunogenic Compositions In Particulate Form And Methods For Producing The Same - The invention relates to the field of immunology and vaccine development, in particular to the development of vaccines based on native antigen oligomers. Provided is an immunogenic composition in particulate form, comprising oligomers of a surface exposed polypeptide of pathogenic origin or tumour origin, or antigenic part thereof, said oligomers being bound non-covalently to a particulate carrier, and a pharmaceutically acceptable diluent or excipient. Also provided is a recombinant polypeptide comprising (A) an N- or C-terminal antigenic domain, comprising at least one surface exposed polypeptide of pathogenic or tumour origin, or antigenic part thereof, the antigenic domain being fused to (B) an oligomerization domain (OMD), said oligomerization domain being fused via (C) a linker domain to (D) a peptidoglycan binding domain (PBD) consisting of a single copy of a LysM domain capable of mediating the non-covalent attachment of the polypeptide to a non-viable bacterium-like particle (BLP) obtained from a Gram-positive bacterium. | 04-03-2014 |
20140134205 | COMPOSITIONS, METHODS AND USES FOR DENGUE VIRUS SEROTYPE-4 CONSTRUCTS - Embodiments herein report compositions, methods and uses for dengue-4 (DENV-4) virus constructs. Some embodiments concern a composition that includes, but is not limited to, DENV-4 virus constructs alone or in combination with other constructs, can be used in a vaccine composition to induce an immune response in a subject. In certain embodiments, compositions can include constructs of more than one serotypes of dengue virus, such as dengue-1 virus, dengue-2 virus, or dengue-3 virus in combination with DENV-4 virus constructs disclosed herein. In other embodiments, DENV-4 constructs disclosed herein can be combined in a composition with other flavivirus constructs to generate a vaccine against more than one flavivirus. Other embodiments provide methods and uses for DENV-4 virus constructs in vaccine compositions that when administered to a subject induce an immune response in the subject against DENV-4 that is improved by modified constructs compared to other vaccine compositions. | 05-15-2014 |
20140147462 | COMPOSITIONS AND METHODS FOR TREATMENT OF HEMATOLOGICAL MALIGNANCIES - Use of a chimeric protein selected from the group consisting of CTLA4-FasL and CD40-FasL proteins for treatment of lymphoma and/or a multiple myeloma and/or a leukemia as described herein, and pharmaceutical compositions and methods of treatment thereof. | 05-29-2014 |
20140147463 | VACCINE AGAINST RSV - Provided is a vaccine against respiratory syncytial virus (RSV), comprising a recombinant human adenovirus of serotype 26 that comprises nucleic acid encoding a RSV F protein or immunologically active part thereof. | 05-29-2014 |
20140154287 | MULTIPLE ANTIGEN PRESENTING IMMUNOGENIC COMPOSITION, AND METHODS AND USES THEREOF - The present embodiments provide for an immunogenic multiple antigen presenting system comprising a polymer to which antigens are associated by complementary affinity molecules. For example, the polymer can be a polysaccharide, or antigenic polysaccharide, to which protein or peptide antigens from the same or different pathogens are indirectly linked. The present immunogenic compositions can elicit both humoral and cellular immune responses to one or multiple antigens at the same time. | 06-05-2014 |
20140205624 | TETRAVALENT AND MIXED HEAD BIVALENT DENGUE VACCINE - The present invention relates to immunogenic compositions and vaccines of flavivirus. In particular, the present invention relates to improved Dengue vaccines and the design and making of such vaccines that enhance immunogenicity of the vaccine. The vaccines and immunogenic compositions of the present invention relate to mixed head bivalent flagellin-dengue antigen fusion proteins which can be combined with other bivalent dengue antigen fusion proteins or monovalent dengue antigen fusion proteins to produce multivalent vaccine including tetravalent vaccines. | 07-24-2014 |
20140220067 | LIVE ATTENUATED CHIMERIC PORCINE CIRCOVIRUS VACCINE - The present invention provides a novel chimeric porcine circovirus infectious DNA clone and live attenuated chimeric virus with the PCV2, preferably of subtype PCV2b, capsid gene integrated into a non-pathogenic PCV1 virus genome. In a particular embodiment, the PCV2 capids gene is of subtype PCV2b, the predominant subtype circulating in pigs worldwide. The attenuated chimeric virus, designated PCV1-2b, effectively protects pigs from PCV2b challenges, and can be used as a live vaccine, as well as an inactivated (killed) vaccine, that provides protection and cross protection against PCV2b and PCV2a subtypes infection. The live attenuated vaccine of the present invention is also effective protecting pigs from porcine circovirus-associated disease (PCVAD). | 08-07-2014 |
20140242107 | Direct Protein Delivery with Engineered Microvesicles - The present invention relates to direct protein delivery with engineered micro vesicles. | 08-28-2014 |
20140248304 | NON-HEMOLYTIC LLO FUSION PROTEINS AND METHODS OF UTILIZING SAME - The present invention provides recombinant proteins or peptides comprising a mutated listeriolysin O (LLO) protein or fragment thereof, comprising a substitution or internal deletion of the cholesterol-binding domain or a portion thereof, fusion proteins or peptides comprising same, nucleotide molecules encoding same, and vaccine vectors comprising or encoding same. The present invention also provides methods of utilizing recombinant proteins, peptides, nucleotide molecules, and vaccine vectors of the present invention to induce an immune response to a peptide of interest. | 09-04-2014 |
20140286987 | METHODS FOR CONTROLLING T CELL PROLIFERATION - The technology relates generally to the field of immunology and relates in part to compositions and methods for controlling the proliferation of T cells, for example, therapeutic T cells. The methods further relate to compositions and methods for inducing an immune response in a subject. | 09-25-2014 |
20140348871 | Composition Comprising the Amyloid Beta 1-6 Peptide Coupled to a Virus-Like Particle and an Adjuvant - The present invention relates to compositions comprising a construct comprising the Aβ1-6 peptide and a pharmaceutically acceptable adjuvant, for the treatment of patients suffering from dementia, in particular dementia of the Alzheimer's type. | 11-27-2014 |
20140356392 | MODULATORS OF MYC, METHODS OF USING THE SAME, AND METHODS OF IDENTIFYING AGENTS THAT MODULATE MYC - Disclosed herein are methods of modulation of the viability of a cell. Further disclosed herein are methods of modulating an immune response. Further disclosed herein are methods of identifying agents capable of modulation of the viability of a cell or an immune response. Further disclosed herein are agents and compositions capable of modulation of the viability of a cell or an immune response. | 12-04-2014 |
20140370045 | USE OF THE CD2 SIGNALING DOMAIN IN SECOND-GENERATION CHIMERIC ANTIGEN RECEPTORS - The present invention provides compositions and methods for treating cancer in a human. The invention includes relates to administering a genetically modified T cell expressing a CAR having an antigen binding domain, a transmembrane domain, a CD2 signaling domain, and a CD3 zeta signaling domain. The invention also includes incorporating CD2 into the CAR to alter the cytokine production of CAR-T cells in both negative and positive directions. | 12-18-2014 |
20140377301 | Vault Compositions for Immunization - Methods and compositions are provided herein for immunizing a subject by administering to the subject an effective amount of an immunogenic peptide or an immunogenic fragment or variant thereof incorporated within a vault-like particle carrier. The methods and compositions advantageously exhibit enhanced ability to induce cell-mediated immunity and/or antibody-based immunity. | 12-25-2014 |
20150044251 | STABLE COMPOSITIONS FOR IMMUNISING AGAINST STAPHYLOCOCCUS AUREUS - Adding stabilizing additives to immunogenic compositions is effective in enhancing antigen stability. Suitable stabilizing additives include EDTA (ethylenediaminetetraacetic acid), sucrose, arginine, protease inhibitors, glycerol and/or citrate. | 02-12-2015 |
20150044252 | CORRELATION OF DISEASE ACTIVITY WITH CLONAL EXPANSIONS OF HUMAN PAPILLOMAVIRUS 16-SPECIFIC CD8+ T-CELLS IN PATIENTS WITH SEVERE EROSIVE ORAL LICHEN PLANUS - A massive clonal expansion of activated CD8 | 02-12-2015 |
20150064209 | METHODS FOR GENERATING IMMUNITY TO ANTIGEN - Provided are methods of generating an immune response to an antigen. The method comprises priming an individual by administering an expression vector encoding the antigen. The vector comprises a transcription unit encoding a secretable fusion protein, the fusion protein containing an antigen and CD40 ligand. Administration of a fusion protein containing the antigen and CD40 ligand is used to enhance the immune response above that obtained by vector administration alone. The methods may be used to generate an immune response against cancer expressing a tumor antigen such as a mucin or human papilloma viral tumor antigen and to generate an immune response against an infectious agent. Also provided is a method for simultaneously producing the expression vector and the fusion protein. | 03-05-2015 |
20150064210 | HUMORAL IMMUNE RESPONSE AGAINST TUMOR ANTIGENS AFTER TREATMENT WITH A CANCER ANTIGEN SPECIFIC ACTIVE IMMUNOTHERAPY AND ITS ASSOCIATION WITH IMPROVED CLINICAL OUTCOME - Compositions and methods are provided herein for predicting therapeutic outcome by measuring patient response to cellular antigen specific active immunotherapy (CASAI) using predetermined biomarkers. | 03-05-2015 |
20150064211 | SYNTHETIC ACTIVE PEPTIDE FRAGMENTS - The present invention relates to peptide fragments which have one or more shared and/or similar amino acid sequences to amino acid sequences of specific portions of the 14 kDa protein of | 03-05-2015 |
20150071960 | HUMAN iNKT CELL ACTIVATION USING GLYCOLIPIDS WITH ALTERED GLYCOSYL GROUPS - Glycosphingolipids (GSLs) bearing α-glucose (α-Glc) that preferentially stimulate human invariant NKT (iNKT) cells are provided. GSLs with α-glucose (α-Glc) that exhibit stronger induction in humans (but weaker in mice) of cytokines and chemokines and expansion and/or activation of immune cells than those with α-galactose (α-Gal) are disclosed. GSLs bearing α-glucose (α-Glc) and derivatives of α-Glc with F at the 4 and/or 6 positions are provided. Methods for iNKT-independent induction of chemokines by the GSL with α-Glc and derivatives thereof are disclosed. Methods for immune stimulation in humans using GSLs with α-Glc and derivatives thereof are provided. | 03-12-2015 |
20150086584 | MULTI-SPECIFIC BINDING AGENTS - Compositions comprising aptamers or other binding ligands provide immune cell regulatory signals and specificity to secreted cell molecules at in vivo foci of immune activity. | 03-26-2015 |
20150110831 | COMPOSITIONS AND METHODS - The invention relates to a composition suitable for inducing a T cell mediated immune response against an influenza virus in a vertebrate, said composition comprising nucleic acid encoding one or more epitopes of one or more internal proteins of influenza virus, wherein said composition comprises nucleic acid encoding at least two said epitopes, at least one epitope being from each of two or more internal proteins of influenza virus. The invention also relates to uses of same and to methods involving same. | 04-23-2015 |
20150140027 | Antigens and Vaccines Directed Against Human Enteroviruses - The instant invention provides materials and methods for producing immunologically active antigens derived from members of the Picornaviridae virus family. The picornavirus antigens of the invention may be in a form for use as a vaccine administered to a subject in a therapeutic treatment or for the prevention of a picornavirus infection. The picornavirus antigens of the invention may be in the form of an immunogenic composition for use in vaccines which are administered for the prevention of an Enterovirus infection. The instant invention further encompasses immunogenic compositions comprising Human enterovirus A, Human enterovirus B, Human enterovirus C, Human enterovirus D antigens and their use in vaccines for the prevention of an Enterovirus infection. | 05-21-2015 |
20150140028 | Recombinant Bacterium and Uses Thereof - The present invention relates to a recombinant bacterium expressing an antigen that is translocated to the cytosol of a host organism, and uses thereof. To this end, the present invention provides a recombinant bacterium comprising a nucleic acid encoding an antigen that is translocated to the cytosol of a host cell utilizing Type III secretion system. The recombinant bacterium is generally chosen from intracellular pathogens that reside in the phagosome and fail to induce rapid T cell activation. The translocated antigen may be a viral antigen, a bacterial antigen, or a tumour antigen. Methods of imparting immunity using the recombinant bacterium are also provided. | 05-21-2015 |
20150147350 | Method Of Treating Cancer With MEGEA3 Immunotherapeutic With BRAF Inhibitor And/Or MEK Inhibitor - A combination of anti-neoplastic agents that provides increased activity over monotherapy, or in some cases at least an unexpected lack of negative interaction. In particular, the drug combination that includes a MAGE-A3 immunotherapeutic, in combination with a B-Raf inhibitor, particularly N-{3-[5-(2-Amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide, or a pharmaceutically acceptable salt thereof, and/or a MEK inhibitor, particularly N-{3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethy; -2,4,7-trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-1-yl]phenyl}acetamide, or a pharmaceutically acceptable salt or solvate thereof is described. | 05-28-2015 |
20150306193 | COMPOSITIONS AND METHODS FOR TREATING IMMUNE CONDITIONS, INCLUDING TYPE 1 DIABETES - The present invention provides a vaccine, immunogenic polypeptide, and pharmaceutical compound, all including a serpinB13 protein or polypeptide or an immunogenic polypeptide that includes a serpinB13 protein or polypeptide coupled to an immunogenic agent. The present invention further includes use of these agents according to a method of inhibiting or delaying onset, or reducing the severity of type 1 diabetes, as well as a method of treating an individual for an immune condition selected from the group of psoriasis, hair loss, and ulcers including diabetic food ulceration. | 10-29-2015 |
20150306206 | FUNCTIONAL INFLUENZA VIRUS-LIKE PARTICLES (VLPS) - Recombinant influenza virus proteins, including influenza capsomers, subviral particles, virus-like particles (VLP), VLP complexes, and/or any portions of thereof, are provided as a vaccine for influenza viruses. The invention is based on the combination of two vaccine technologies: (1) intrinsically safe recombinant vaccine technology, and (2) highly immunogenic, self-assembled protein macromolecules embedded in plasma membranes and comprised of multiple copies of influenza virus structural proteins exhibiting neutralizing epitopes in native conformations. More specifically, this invention relates to the design and production of functional homotypic and heterotypic recombinant influenza virus-like particles (VLPs) comprised of recombinant structural proteins of human influenza virus type A/Sydney/5/94 (H3N2) and/or avian influenza virus type A/Hong Kong/1073/99 (H9N2) in baculovirus-infected insect cells and their application as a vaccine in the prevention of influenza infections and as a laboratory reagent for virus structural studies and clinical diagnostics. | 10-29-2015 |
20150335720 | PRODUCTION OF BIOLOGICALLY ACTIVE PROTEINS - A fusion protein that is expressed in a recombinant protein body-like assembly (RPBLA) in host eukaryotic cells and organisms is disclosed. More particularly, a biologically active polypeptide fused to a protein sequence that mediates the induction of RPBLA formation is expressed and accumulated in host cells after transformation with an appropriate vector. The eukaryotic host cell does not produce protein bodies in the absence of the fusion protein. Methods for preparing and using the RPBLAs and the fusion protein are also disclosed, as are nucleic acid molecules that encode the fusion proteins. | 11-26-2015 |
20160008452 | Vault Compositions for Immunization | 01-14-2016 |
20160015797 | VACCINE FOR UTI WITH TRUNCATED FORM OF FLAGELLIN (FliC) FROM ENTEROAGGREGATIVE ESCHERICHIA COLI FUSED WITH FimH PROTEIN - The embodiments herein discloses a vaccine against urinary tract infection (UTI). The flagellin (FliC) of enteroaggregative | 01-21-2016 |
20160030552 | IMMUNE MODULATION - The present invention relates to a poxvirus vector comprising a nucleic acid sequence encoding a fusion protein comprising: (i) a peanut allergen selected from list consisting of at least two peanut allergens from ara h 1, ara h 2, ara h 3, ara h 4, ara h 5, ara h 6. ara h 7, ara h 8, ara h 9, ara h I O and ara h I I or a derivative or part thereof having at least 70% sequence identity thereto, and (ii) a profeasome degradation tag to enhance intracellular degradation of the fusion protein. Methods of desensitizing or inducing tolerance to a peanut allergen and/or suppressing an allergic response to a peanut allergen are also disclosed. | 02-04-2016 |
20160039884 | Metapneumovirus Immunogens and Related Materials and Methods - The present invention provides compositions useful to induce immune response to human | 02-11-2016 |
20160046676 | FUSION POLYPEPTIDES AND VACCINES - The present invention relates to novel immunogenic polypeptides and their use in vaccine compositions. The invention also relates to nucleic acids, vectors and cells which express the polypeptides and the uses thereof. The polypeptides of the invention more specifically comprise an immunogenic domain and a cell membrane addressing domain which is derived from a B5R gene. The invention is particularly suited to produce vaccines for non-human animals, particularly for vaccinating swine against PCV2 infection. | 02-18-2016 |
20160058857 | COSTIMULATION OF CHIMERIC ANTIGEN RECEPTORS BY MYD88 AND CD40 POLYPEPTIDES - The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen. The technology also relates to costimulation of therapeutic cells that express chimeric antigen receptors that recognize target antigens using chimeric MyD88- and CD40-derived polypeptides. The technology further relates in part to therapeutic cells that express chimeric antigen receptors, wherein the chimeric antigen receptors have an endodomain that includes MyD88- and CD40-derived polypeptides, and methods for treating patients using the modified therapeutic cells. | 03-03-2016 |
20160089427 | Genetically Modified Yersinia as Vaccines Against Yersinia Species - Recombinant attenuated | 03-31-2016 |
20160114035 | PAN-DR Binding Polypeptides and Uses Thereof - The present invention provides novel artificial oligopeptides capable of binding HLA Class II molecules encoded by several alleles. The oligopeptides include the sequence AX | 04-28-2016 |
20160120974 | SEMI-LIVE RESPIRATORY SYNCYTIAL VIRUS VACCINE - The present invention relates to a semi-live respiratory syncytial virus (RSV) vaccine, which comprises a genome replication-deficient Sendai virus (SeV) vector expressing a chimeric RSV/SeV F protein. Furthermore, the present invention relates to a method for the production of the genome replication-deficient SeV vector of the present invention, and the use thereof in the treatment of RSV infections and RSV infection-related diseases. | 05-05-2016 |
20160137699 | RECOMBINANT FUSION ANTIGEN GENE, RECOMBINANT FUSION ANTIGEN PROTEIN AND SUBUNIT VACCINE COMPOSITION HAVING THE SAME AGAINST INFECTION OF PORCINE REPRODUCTIVE AND RESPIRATORY SYNDROME VIRUS - The present invention is directed to a recombinant fusion antigen gene, a recombinant fusion antigen protein and a subunit vaccine composition having the same against infection of porcine reproductive and respiratory syndrome virus (PRRSV). A recombinant fusion antigen gene, which encodes glycoprotein GP5 with truncated N′-terminal decoy epitope, a linker sequence and membrane protein M, followed by codon optimization, is expressed by a baculovirus expression system in vitro, thereby enhancing a yield of the recombinant fusion antigen protein. The recombinant fusion antigen protein can be applied in a subunit vaccine composition, for providing vaccinated animals with better protection ability without the risks of virulent spread and virulent recovery. | 05-19-2016 |
20160166678 | COMBINATION VACCINE | 06-16-2016 |
20160376556 | KIDNEY-SPECIFIC TUMOR VACCINE DIRECTED AGAINST KIDNEY TUMOR ANTIGEN G-250 - This invention provides an anti-cancer immunogenic agent(s) (e.g. vaccines) that elicit an immune response specifically directed against renal cell cancers expressing a G250 antigenic marker. Preferred immunogenic agents comprise a chimeric molecule comprising a kidney cancer specific antigen (G250) attached to a granulocyte-macrophage colony stimulating factor (GM-CSF). The agents are useful in a wide variety of treatment modalities including, but not limited to protein vaccination, DNA vaccination, and adoptive immunotherapy. | 12-29-2016 |
20170232082 | SYNTHETIC ACTIVE PEPTIDE FRAGMENTS | 08-17-2017 |